Computational prediction of interactions between Paxlovid and prescription drugs.
Yeji KimJae Yong RyuHyun Uk KimSang Yup LeePublished in: Proceedings of the National Academy of Sciences of the United States of America (2023)
Pfizer's Paxlovid has recently been approved for the emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for the treatment of mild-to-moderate COVID-19. Drug interactions can be a serious medical problem for COVID-19 patients with underlying medical conditions, such as hypertension and diabetes, who have likely been taking other drugs. Here, we use deep learning to predict potential drug-drug interactions between Paxlovid components (nirmatrelvir and ritonavir) and 2,248 prescription drugs for treating various diseases.
Keyphrases
- drug administration
- coronavirus disease
- sars cov
- healthcare
- deep learning
- drug induced
- type diabetes
- blood pressure
- emergency department
- public health
- cardiovascular disease
- machine learning
- adipose tissue
- convolutional neural network
- antiretroviral therapy
- metabolic syndrome
- combination therapy
- skeletal muscle
- weight loss
- replacement therapy